AstraZeneca, US6549022043

AstraZeneca stock gains as NHS approval lifts Enhertu access

Published on 09/17/2026 at 14:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock gained 1.2 percent to 122.85 GBP on September 17, 2026. Reuters said NICE cleared Enhertu for NHS use in England, with about 1,000 women eligible.

Fotorealistisches Pharmaforschungslabor mit Wissenschaftlern in weißen Kitteln an Mikroskopen und Analysegeräten bei hellem klinischen Licht — AstraZeneca US6549022043 zeigt modernes Pharma Forschungslabor mit Wissenschaftlern an Mikroskopen und Analysegeräten, Illustration mit AI erstellt.

AstraZeneca stock (ISIN US6549022043) rose 1.2 percent to 122.85 GBP on September 17, 2026, with 100,338 shares traded by 09:28 and a 52-week high of 157.30 GBP. Reuters said the catalyst was NICE approval for Enhertu in England, a ruling that expands NHS access for the breast cancer drug.

Enhertu gets a UK lift

According to Reuters on September 17, 2026, AstraZeneca and Daiichi Sankyo said Enhertu was approved for use in England's state-run healthcare system. Reuters added that about 1,000 women a year will be eligible and that the UK list price is GBP 1,455 per 100 mg vial.

The same Reuters report said the approval follows a NICE recommendation based on 2022 trial data showing Enhertu extended survival in some patients by about six months. That gives the stock a concrete operating angle for investors, not just a headline drug event.

UBS still sees upside

According to Proactive Investors on September 16, 2026, UBS kept a Buy rating and cut its price target to 15,200p from 17,600p. The bank said the stock had fallen roughly 15 percent since early July and still implied more than 25 percent upside from the 11,925p close on September 15.

Proactive Investors also reported that Jefferies kept a Buy rating with a 17,500p target after a briefing with Pam Cheng, AstraZeneca's head of global operations. UBS said the company can still reach its $80 billion revenue target by 2030 and trades at about 14.3 times forecast 2027 earnings.

Quarterly numbers still matter

In its most recent quarterly update for the period ended June 30, 2026, AstraZeneca reported revenue of GBP 11.46 billion, up 5.84 percent from GBP 10.83 billion a year earlier. EPS came in at GBP 1.20 versus GBP 1.18 in the prior-year quarter, according to finanzen.ch on September 17, 2026.

For investors, the mix is clear: a 1.2 percent share gain, a 15.2 percent lower UBS target than before, and quarterly revenue growth of 5.84 percent now sit next to each other. That makes the next earnings date on October 30, 2026, the next fixed checkpoint.

122.85 GBP holds the frame

AstraZeneca stock traded at 122.85 GBP on September 17, 2026, still 21.90 percent below the 52-week high of 157.30 GBP and above the 52-week low of 107.84 GBP. Volume reached 100,338 shares by 09:28, while the FTSE 100 stood at 10,765 points.